Palatin Technologies, Inc. (0KF3) Earnings Call Transcript & Summary

September 28, 2026

London Stock Exchange GB Health Care Biotechnology earnings 34 min

Earnings Call Speaker Segments

Operator

operator
#1

Hello, everyone. Welcome to the conference call covering Palatin's operating results for the fourth quarter and fiscal year-end 2026. Right now, everyone is in a listen-only mode. After the formal presentation, there will be a question-and-answer session. Should you need the operator's help at any point during the call, just press *0 on your telephone keypad. Please note that this conference call is being recorded. Before we get into our remarks, I want to remind everyone that statements Palatin makes that are not historical facts may constitute forward-looking statements. Such statements rest on assumptions that might or might not turn out to be accurate, and actual results could differ materially from those anticipated because of the various risks and uncertainties covered in the company's most recent filings with the Securities and Exchange Commission. As you evaluate these forward-looking statements regarding Palatin's prospects, please weigh such risks and uncertainties carefully. Now I'd like to hand the call over to our host, Dr. Carl Spana, Palatin's President and Chief Executive Officer. Please go ahead.

Carl Spana

executive
#2

Morning, everyone, and thanks for being with us. Carl Spana here, President and Chief Executive Officer of Palatin Technologies. I'll start by covering our strategic priorities and how our development programs are progressing. After that, Steve Wills, our Chief Operating Officer and Chief Financial Officer, will walk through the fiscal 2026 financial results and where our liquidity stands. Following that, we'll wrap up with questions. Our main strategic focus is developing next-generation, best-in-class melanocortin 4 receptor, or MC4R, agonists for the treatment of syndromic and rare obesity disorders. At the outset, we are targeting hypothalamic obesity, Prader-Willi syndrome, and Bardet-Biedl syndrome, and these could potentially apply to other disorders that involve the MC4R pathway. MC4R agonism has now been validated both clinically and commercially across multiple rare and syndromic obesity disorders, which gives us a strong foundation for developing next-generation therapies. Palatin contributes over 25 years of experience in melanocortin research and drug development to this opportunity, and that includes developing the FDA-approved bremelanotide, or Vyleesi. Although therapies available today and those emerging have shown meaningful efficacy, gastrointestinal adverse events and hyperpigmentation are still important challenges for patients who need long-term treatment. Clinical studies of the approved MC4R agonist in the rare obesity space, along with the next-generation investigational MC4R therapies currently in development, have continued to report high levels of nausea and vomiting, as well as incidence of hyperpigmentation.

Carl Spana

executive
#3

What we're aiming for is to create melanocortin 4 receptor therapies that rank among the best available, providing efficacy that matches or exceeds current options while offering better tolerability, minimal to no hyperpigmentation, and profiles appropriate for lifetime use. Two complementary peptide series are moving forward in our work: the non-lipidated PL1000 series and the lipidated PL2000 series. Compounds we've tested from each of these series have shown potent MC4R agonism activity and no MC1R agonism. Since activation of MC1R agonism plays a role in pigmentation, these results back our approach of reducing or perhaps even removing hyperpigmentation. Both peptide series feed into our push toward a long-acting therapy given once weekly by subcutaneous injection. In preclinical work, compounds from the PL1000 and PL2000 series alike have generated meaningful dose-dependent decreases in body weight and food intake among diet-induced obese mice. For our PL1000 lead development candidate, we've shown that once-weekly subcutaneous dosing is feasible, and we're now working on optimizing a controlled-release formulation. Our lead MC4R lipidated peptide development candidate has shown meaningful cuts in food intake and weight loss when dosed once weekly subcutaneously in a diet-induced obese mouse model. Preclinical pharmacokinetic data backs the possibility of dosing less often than once weekly, or at longer intervals, in humans. At present we're carrying out the activities needed to file an IND and start human clinical studies. Our oral small-molecule MC4R program offers a third treatment approach, drawing on what we learned from an earlier drug candidate, PL7737, and employing multiple methods, among them artificial intelligence and machine learning tools.

Carl Spana

executive
#4

We’ve found possible drug candidates that show better potency and greater selectivity for MC4R. What we aim to do is create an oral MC4R agonist that can produce efficacy similar to or better than emerging oral MC4R therapies, while offering improved tolerability in the gastrointestinal tract. We’re also designing our oral candidates so that MC1R-mediated off-target activity is limited or avoided, which should minimize or eliminate hyperpigmentation. Assuming we have appropriate funding, we’re aiming to start Phase 1 single ascending dose and multiple ascending dose studies for our lipidated peptide candidate during the first half of calendar 2027, with data targeted for the second half of 2027, and we’re aiming to begin the oral Phase 1 single ascending dose and multiple ascending dose studies in the second half of calendar 2027, with initial data expected in the first half of 2028. Those studies are going to assess human safety, tolerability, pharmacokinetics, and clinical efficacy. Altogether, our non-lipidated peptide, lipidated peptide, and oral small-molecule programs give us three distinct ways to develop differentiated, selective MC4R agonists for the long-term treatment of patients who have syndromic and rare obesity disorders. Every one of these approaches is being designed around the same core, best-in-class objective: meaningful efficacy, improved tolerability, little to no hyperpigmentation, and a dosing profile that is suitable for lifelong treatment.

Carl Spana

executive
#5

Outside of what we're doing in obesity, the wider melanocortin platform has already brought in significant strategic collaborations. Through the retinal disease research collaboration and license agreement we signed in August 2025, Boehringer Ingelheim made an upfront payment plus initial milestones totaling €7.5 million. That agreement also allows for as much as €280 million in further success-based milestones along with tiered royalties. Reimbursed research under this collaboration is still being carried out by us. In addition, earlier this year we sublicensed the PL9643 dry eye program to Antenaspack Labs. Past those partnered assets, positive Phase 2 proof-of-principle findings exist for our PL8177 ulcerative colitis program, and encouraging open-label Phase 2 data are available for our diabetic nephropathy program too. Partnerships are being pursued for these non-core assets, which lets our internal development effort stay concentrated on rare obesity MC4R therapies. Our priorities are plain: move our complementary non-lipidated and lipidated selective MC4R agonist drug candidates and oral program toward clinical development, turn preclinical differentiating findings into human clinical evidence, and keep creating value via our strategic collaborations and partnerships. Steve is going to review our financial results now. Steve, over to you.

Steve Wills

executive
#6

Thanks, Carl, and good morning to all of you. I'll walk through the results for our fiscal fourth quarter and for the full year 2026, and then I'll cover where we stand on cash and how we see liquidity going forward. Except where I say otherwise, the comparisons are against the matching periods of fiscal year 2025. In the fourth quarter, which closed on June 30th, 2026, Palatin booked $300,000 of collaboration and license revenue, versus no revenue in the same quarter a year earlier. Across the entire fiscal year, collaboration and license revenue came to $13.2 million, versus no revenue in fiscal 2025. That figure included $9.4 million tied to our collaboration with Boehringer Ingelheim and $3.8 million tied to the Antenaspack sublicense. The Antenaspack revenue came in the form of cancellation of debt on a non-cash basis. Operating expenses for the fourth quarter were $4.7 million, versus $2.3 million in the comparable quarter of the prior year. That prior-year quarter contained gains connected to Vyleesi and to purchase commitments, which affects how comparable the numbers are. Research and development expense came to $2.0 million in both fourth quarters, and general and administrative expense was $2.7 million, versus $2.6 million a year earlier. For fiscal 2026 overall, total operating expenses reached $21.9 million, versus $17.5 million in fiscal 2025. Research and development expenses fell to $12.4 million from $14.9 million, largely because of lower expenses tied to the timing of certain activities within our MC4R programs.

Steve Wills

executive
#7

G&A expenses rose to $9.5 million from $7.8 million, mainly because professional fees were higher. Operating expenses for fiscal 2025 included a $3.1 million gain on the sale of Vyleesi and a $2.1 million gain on purchase commitments. We posted a fourth quarter net loss of $4.4 million, versus $2.2 million in the prior-year quarter. For the full fiscal year, net loss fell to $8.4 million, or a loss of $2.96 per basic and diluted common share, compared with a net loss of $17.3 million, or a loss of $32.15 per basic and diluted common share, in fiscal 2025. The year-over-year improvement in net loss came primarily from collaboration and license revenue and gains related to Vyleesi and purchase commitments. Net cash used in operating activities was $13.5 million in fiscal 2026 compared with $21.3 million in fiscal 2025. Net cash provided by financing activities was $18.5 million, consisting primarily of $16.9 million in net proceeds from common stock and warrant sales and $1.6 million from warrant exercises. Turning to liquidity, we ended June 30th, 2026 with $7.5 million in cash and cash equivalents compared with $2.6 million at June 30th, 2025. Current liabilities were $1.8 million at fiscal year-end.

Steve Wills

executive
#8

With that cash balance in mind, and given our present operating and development plans—including our ability to cut back on or postpone some expenditures that management controls—we don't anticipate that our existing cash will be enough to fund operations for at least 12 months after our financial statements are issued. So there is substantial doubt regarding our capacity to continue as a going concern. To keep moving our development programs forward and to fund operations, we will need additional financing. We plan to seek equity financings, collaboration arrangements, and other possible sources of capital, though we can't guarantee that funding will be available when it's needed or on acceptable terms. When the planned development milestones happen will still depend on having appropriate funding. On the operational side, we're putting priority on our peptide and oral MC4R obesity programs, carrying out our collaboration obligations, and looking for opportunities to realize value from our partnered and partnering assets. That wraps up my financial review. Carl, I'll hand the call back to you for closing comments and questions.

Carl Spana

executive
#9

Thank you, Steve. What we're concentrating on is turning the encouraging preclinical results — from the non-lipidated peptides as well as the lipidated ones, along with our oral small-molecule program — into clinical proof. The therapies we're developing are melanocortin 4 receptor agonists, built to deliver meaningful efficacy, better tolerability, and little to no hyperpigmentation for patients who have rare obesity disorders. Thanks for being with us. We're ready now to take your questions.

Operator

operator
#10

Thank you. Ladies and gentlemen, we are now ready to take questions from the floor. Should you want to enter the queue to pose a question at this time, kindly press *1 on your telephone keypad. We do ask, if you are listening on speakerphone this morning, that you lift your handset while asking your question so that sound quality is optimal. Once again, please press *1 on your telephone keypad at this time if you would like to join the queue to ask a question. Please hold a moment while we poll for questions. Your first question this morning comes from Scott Henry from AGP. Scott, your line is live. Please go ahead.

Scott Henry

analyst
#11

Thanks, and good morning. Carl, I’ll begin with your question. You brought up the lipidated peptide approach and the non-lipidated peptide approach. Would you speak a bit about what each one offers and how they differ, and in the end would you reduce it to a single one, or would you continue with both all the way? Thank you.

Carl Spana

executive
#12

Thanks, Scott. The key distinction is this: with a lipidated peptide, there's an aliphatic portion that binds to plasma proteins, so the durability is inherent in the molecule itself. No formulation or polymer formulation is needed. It works much like what you'd observe with the GLP-1s. With the non-lipidated version, you're formulating into erodible polymers that get injected and then break down over a set period, releasing the drug gradually. Long-term delivery can be achieved either way. We'd lean toward the lipidated approach because it offers somewhat more flexibility. You aren't reliant on how the polymer releases, since essentially you're making a single API — no formulation involved — and it's less bulky at the injection site. We think it will also provide the greatest flexibility for dose titration; you can have multiple doses, or more readily have multiple doses used in a titrating manner, much like what's done with the GLP-1s today. In my view, it gives the clinician and the patient the most flexibility compared with the polymer approach. We'll run both of those in parallel.

Carl Spana

executive
#13

What we're aiming for, as we've said, is a product dosed weekly that delivers strong efficacy—meaning high MC4R selectivity and potency, with hyperpigmentation limited to none. Naturally, our preference would be simply to carry the lipidated one forward, and once that enters the clinic and starts demonstrating efficacy, we'd likely put less emphasis on the polymer program. Advancing both of them all the way into Phase 2 clinical development is probably not what we'd do. We'd make a call.

Scott Henry

analyst
#14

Thanks. That's helpful context. I know hyperpigmentation has come up quite a bit from you. I did pick up a few additional details on making gastrointestinal tolerability better. Specifically, what steps are you taking to tackle that issue with the MC4R agonist?

Carl Spana

executive
#15

Absolutely. You can look at it two ways. First, the GI side effects really do come from MC4R agonism. A way to lessen that is basically to avoid giving patients too much. If you use, say, the lipidated peptide, it's much simpler to keep the patient within the therapeutic range you're aiming for without overshooting. A difficulty with those simpler peptides that aren't formulated is that you're giving a large bolus injection, correct, since it's a short-acting drug, you go far above the therapeutic window for the drug, and then you end up with higher levels of AE. One approach is just by smoothing out how the drug is absorbed and holding it in a flat therapeutic window, you'll reduce some of the GI side effects, and you'll be left with, say, some of the inherent effects that happen simply from activating the receptor. A second method, which is a bit more complicated, is to try to develop compounds that by their nature have no ability at all to cause nausea and emesis, and there are structural elements we're working on that can lead to that, but we're not quite there yet. At present, the main way you're going to accomplish this is really by limiting essentially that bolus dosing, keeping it in that flat therapeutic window.

Carl Spana

executive
#16

Ideally, you'd accomplish that using these lipidated peptides.

Scott Henry

analyst
#17

Great. Carl, here's the last question for you. Have you thought about which rare obesity indication you'd probably go after first? Yes.

Carl Spana

executive
#18

My guess is that hypothalamic obesity will be the initial indication. There are some benefits in that case, since those patients are fairly simple to spot. They've had a form of cancer whose treatment damages the hypothalamus, and they're generally healthy people who basically have hypothalamic damage that an MC4R agonist can fix. That would be the first indication. Prader-Willi syndrome would likely also be pursued quite near in time, if not concurrently. That one is somewhat different. You're addressing the hyperphagia and attempting to bring down some of the obesity too. Then Bardet-Biedl syndrome would be third. Those are the three, more or less in that sequence. For the first two, I think we would, resource permitting, aim to conduct them concurrently, as near to concurrently as we can.

Scott Henry

analyst
#19

Thanks, Carl. I’ve got a couple of questions for Steve. Steve, how should we think about collaboration and license revenue in fiscal year 2027? Should it be material or significant? I’m just trying to get a sense of it relative to what we saw in fiscal 2026.

Steve Wills

executive
#20

Thanks, Scott. From where we sit, hitting any milestone through these partnerships matters a great deal. To give you the backdrop, we have 2 collaborations currently underway: 1 in the ocular space with Boehringer Ingelheim, and another in the ocular space with Antenaspack. We anticipate and expect a milestone from Boehringer Ingelheim to land at some point over the coming 2 to 3 quarters. Antenaspack sits somewhat further out. Beyond those existing, active collaborations, interest does exist. We're seeing quite strong interest in a few of our other programs outside obesity — in particular our ulcerative colitis work, plus certain other ocular indications, and an MC1R autoimmune and anti-inflammatory program. I can't yet say we expect to land something over the next several quarters, but it wouldn't surprise us if someone does pull the trigger on a research or early-stage collaboration along those lines.

Scott Henry

analyst
#21

Thanks. Now on OpEx trends — clearly they were lower in Q4. As you get ready to push things forward more aggressively, should we be expecting OpEx to rise sequentially across 2027?

Steve Wills

executive
#22

At first, yes. During the quarter that closed on June 30th, and likewise in the quarter right before it, some of these activities happen in sequence. Depending on timing, there will be some fluctuation. We expect that over the coming several quarters — let's say the quarter ending 12/31 and the first quarter, or honestly even the first half of '27 — the figure will rise. It won't double, so to speak; it will more likely land around what we recorded during the first few quarters of calendar '26. Once again, we're pushing the program ahead, and I know folks like to say, "Oh, you're spending money." What we're doing is investing that money. We couldn't be happier with our position from a differentiation standpoint within the obesity space, where we're continuing to move forward with.

Scott Henry

analyst
#23

Okay, last question: regarding the balance sheet and how funding is developing, are we still considering those warrants — I think they were the Series J warrants that got activated, I believe, through an IND acceptance — is that still part of the financing picture? Thanks.

Steve Wills

executive
#24

The funding picture is 100% inclusive of that, which is exactly why we structured it this way. Within the November 2025 financing, there was what we refer to as a short-term warrant. The Series J warrant is the right one. That actually sets off the trigger, and it gets triggered at whichever comes first: 18 months, or the IND filing for one of our internal obesity MC4R compounds. Exercising it at 100% would produce roughly $18.5 million. So that 100% forms part of future funding, and if we reach that trigger, things are going well.

Scott Henry

analyst
#25

Perfect, that helps a lot, and thanks to both of you for fielding all our questions.

Operator

operator
#26

Appreciate it. Up next, we have a question from Yale Jen at Laidlaw & Company. Yale, your line is open, so please proceed.

Yale Jen

analyst
#27

Morning, and thank you for taking the questions. My first question concerns the PL2000. That's the lipidated product candidates you expect to begin trials for in the first half of next year — calendar next year. What IND-enabling work still remains before you're able to start filing and the Phase 1 studies? I have a follow-up after that.

Carl Spana

executive
#28

Absolutely. What's really left is mainly completing that first round of animal toxicology work. At this point we're scaling up, and those studies are on the calendar and being prepared to begin, yet that piece represents by far the biggest chunk of what remains for us. There are invariably various additional earlier-stage or in vitro studies as well, though many of those are already complete. The key is finishing the animal studies and having the reports in hand.

Yale Jen

analyst
#29

Did any manufacturing work need to be done, or would that be

Carl Spana

executive
#30

As soon as you designate the compound, the manufacturing effort is continuous. We're able to produce them under cGMP conditions at this point, and we'll keep at it—continuing to work on enhancing efficiencies in scale, formulation, and so forth. That process truly never ends. Going forward, there will always be some level of manufacturing activity underway. That's fairly standard across most programs.

Yale Jen

analyst
#31

Yes, of course. With regard to lipidated compared with non-lipidated, the lipidated form will typically show perhaps a longer half-life and possibly stronger activity — biological activity, that is. So when you look at your lipidated version against the earlier non-lipidated one, did you see any meaningful difference on some of those metrics?

Carl Spana

executive
#32

Sure. Let me step back for a moment and discuss lipidated peptides, specifically regarding melanocortins. Achieving lipidation of one of these peptides while preserving strong MC4R selectivity and potency was no small feat. A great deal of effort went into that. You cannot simply attach any kind of aliphatic tail to one of these peptides and assume it will function. That is not how it works. Part of this relates to the character of patents that have been submitted and that continue to be submitted. A technological breakthrough was required in order to genuinely achieve effective lipidated peptides. One thing we are observing is that, when examining pharmacokinetics across several species, rodent and non-rodent alike, we are seeing very extended half-lives. One point that makes us optimistic is that there is a strong likelihood these peptides will be dosed less than once a week, which means we may be able to administer them once every two weeks. That is something we are genuinely enthusiastic about, and it is something we did not anticipate when we began, but as we now examine and model it, it appears we will have real potential for longer dosing intervals, which is quite pleasing.

Yale Jen

analyst
#33

Thanks, that's really useful. Maybe just a single follow-up on that point: when you put your lipidated 2000 up against, say, Rhythm's next-gen weekly-administered product, do you happen to know if their molecule is lipidated or not?

Carl Spana

executive
#34

From what I understand and can tell, they're taking a polymer approach. They have a potent MC4R agonist that they've placed in a polymer that, based on the limited information available, I would presume erodes over roughly a week and releases the drug. It's a different approach. They aren't using the lipidated approach. They're using the polymer approach.

Yale Jen

analyst
#35

Okay, so perhaps just a couple of fast questions. Regarding the oral drugs, what lessons would you say you've taken away from the earlier 7737, and what kind of enhancement do you believe you'd want to incorporate before you'd feel at ease advancing that program into a clinical study?

Carl Spana

executive
#36

Absolutely. Naturally, we would rather have seen that compound advance. At the conclusion of the toxicology studies, we did identify a tox issue. We understand well what it was, and we have since pursued several approaches. Before 7737, we had a number of scaffolds in progress that showed better selectivity, very strong potency, and improved selectivity. Those are now being optimized, several of them in parallel. Then, with the 7737 series, once we understood what might be problematic about it from a drug perspective, we were able to correct that, and those analogs are now being optimized as well; they will be fully evaluated and will move forward. On that front, we learned a great deal, and we understand what it takes to get one of these optimized and moving ahead. We now have several scaffolds, the 7737 scaffold among them, to take forward. What we also learned is that these can be quite potent across multiple animal species. We did observe truly excellent weight loss. What's encouraging is that it's very clear: if you get it right, you ought to be able to achieve really strong efficacy with an MC4R small molecule.

Yale Jen

analyst
#37

Are you expecting to begin the IND-enabling study around the end of the year, or will that happen in 2027?

Carl Spana

executive
#38

Look, we're working very hard to get the compound selected by year-end and to kick off the IND-enabling studies that will land us in the clinic during the second half of the year.

Yale Jen

analyst
#39

Okay. Perhaps the final question — just out of curiosity regarding PWS, since a drug clearly received approval in recent days. Do you believe that in the end, whichever compound you choose for PWS will be used as a monotherapy, or do you think there's potential for a combination given the differing mechanisms of action? Thanks for taking the questions.

Carl Spana

executive
#40

Okay, so I think over time, especially for many of these rare syndromic conditions — HO and Prader-Willi in particular — you'll probably see a fair number of patients eventually transition to combination therapy. That said, I don't think it will necessarily involve DCCR, the drug that's currently approved. That drug does work, and it is the first approved one, and I'll just leave it there. My view is that an MC4R agonist can likely deliver better tolerability, better safety, and better efficacy than what's available today. And when you pair that with, say, the GLP-1s, there's potential to achieve even stronger efficacy. For these patients, I think polypharmacy will certainly depend heavily on how the patient responds initially to MC4R agonism, and on whether moving in that direction is needed. What's encouraging is that there's an opportunity to keep pushing the therapeutic envelope by adding another drug.

Yale Jen

analyst
#41

Thanks a lot. Appreciate the update, and good luck going forward.

Carl Spana

executive
#42

I appreciate that.

Operator

operator
#43

Thank you. Dev Prasad from Lucid Capital Markets has the next question. Dev, your line is open, so please go ahead.

Dev Prasad

analyst
#44

Hello, and congratulations on the progress. Thanks for taking our question. We have a couple of questions. First, you said that the tested compound from both peptide series is not an agonist at MC1R. Could you give us a bit more color on the quantification of the MC4R versus MC1R selectivity margin compared with the previous Palatin compound? The next question is about the clinical trial. How are you planning those trials in terms of design, and what do you want to learn from Phase 1 for both the peptide and the oral? Thank you.

Carl Spana

executive
#45

Okay, sure. Broadly speaking, I won’t go too deeply into how we describe the agonism here. This space has gotten quite competitive. It isn’t only Rhythm and Palatin—other companies are also examining this. A key reason we refer to 1000 and 2000, among others, is that we want to preserve as much competitive advantage as we can for as long as we can, so people can’t simply search through patents and instantly begin to see what the lead compound is like. To answer your question: we understand how to characterize an agonist, and we think these compounds have minimal MC1R agonism, which clinically should correspond to a meaningful improvement in hyperpigmentation. Then, on the second part, if I recall correctly, you were asking about what clinical trial design?

Dev Prasad

analyst
#46

Sure. What do you expect Phase 1 to teach you?

Carl Spana

executive
#47

So clearly, in the single ascending dose portion of Phase 1, you're giving one dose. What you're really trying to determine is whether there's any obvious acute toxicity, and then what your tolerability window looks like and what your dosing window looks like. Once we get into the multiple ascending dose portion, these patients will now shift to what are called healthy obese patients. They'll receive treatment for 28 days, and we expect to learn a great deal from that. We should be in a position to see efficacy data. We want to find out whether the compounds can actually produce reductions in food intake and weight loss. We'll be watching for long-term tolerability and longer-term safety signals. Once we finish that MAD study, we'll have a fairly solid sense of how well the compounds will work and when we move into the intended patient population, such as hypothalamic or Prader-Willi or the BBS patients. One point about the mechanism is that it translates very, very well across patient populations when it comes to efficacy, as well as tolerability and safety.

Dev Prasad

analyst
#48

Thanks a lot — that’s great.

Operator

operator
#49

Thanks. That brings today's Q&A portion to an end. At this point, I'd like to hand things back over to Dr. Carl Spana for some closing remarks.

Carl Spana

executive
#50

Thanks. I want to express appreciation to all of you for joining us for our year-end and first fiscal quarter. Everyone here is very enthusiastic about what we've achieved. In my view, we've achieved some significant technical advances that are producing what I consider truly best-in-class compounds, backed by solid intellectual property. We're enthusiastic about our current position and our direction. For Palatin, this is genuinely an exciting period, since we've essentially been able to draw on the experience accumulated with this target to create some outstanding compounds that we think will be best-in-class. We're eager to keep bringing you updates on how we're progressing. Steve and I will clearly be speaking with some of you, I believe, over the course of the quarter. Having said that, have a good day, and we're eager to keep you informed. Thanks.

Operator

operator
#51

Thanks. That brings us to the end of today’s conference call. You’re welcome to disconnect now, and I hope you have a wonderful day. Thanks again for joining us.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Palatin Technologies, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Palatin Technologies, Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Palatin Technologies, Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.